DaVita Inc., US23918K1088

DaVita stock holds $180.72 as earnings beat and guidance stand out

Published on 08/31/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita stock held at $180.72 as August 4 results showed $4.02 EPS, $3.55 billion revenue and FY 2026 EPS guidance of 14.1 to 15.2.

Isometrische 3D-Darstellung von Dialyseklinik, Labor, Heimversorgung und integrierter Patientenpflege
Isometrische 3D-Illustration der vollständigen Wertschöpfungskette in der Nierenversorgung von DaVita Inc. US23918K1088, Illustration mit AI erstellt.

DaVita Inc. (US23918K1088) opened at $180.72 on August 31, 2026, with a market value of $11.53 billion and a 52-week range of $101.00 to $247.49. The latest catalyst remains the August 4, 2026 earnings update, where the company posted $4.02 in adjusted EPS on $3.55 billion in revenue.

Earnings still shape the tape

The August 4 quarter came in ahead of expectations on both lines, with EPS $0.14 above the $3.88 consensus and revenue $50 million above the $3.50 billion estimate. Revenue also rose 5.2% from $2.95 billion in the same quarter a year earlier, while FY 2026 guidance stands at $14.10 to $15.20 EPS.

That mix matters because the stock is trading below its 50-day average of $211.96 and slightly above its 200-day average of $183.37, which places the current quote between a shorter-term pullback and a longer trend reference.

Consensus stays cautious

Broker coverage still leans neutral. The current consensus view sits at Hold with an average target of $221.75, while the shares also carry a P/E ratio of 14.79 and a PEG ratio of 0.47.

Institutional activity has also been active this month. One recent filing showed Manufacturers Life Insurance added 29,392 shares valued at $6.54 million, while another showed Jupiter Topco bought 40,588 shares worth $9.03 million.

Kidney care remains core

DaVita's core business is outpatient kidney care, including in-center hemodialysis, peritoneal dialysis and home dialysis therapies. The company also offers patient education, nutritional counseling and vascular access management, which keeps its revenue base tied to treatment volume and care delivery rather than one-off products.

For investors, the key numbers now are simple: $180.72 on August 31, 2026, $11.53 billion in market cap, and an August 4 quarter that delivered $4.02 EPS on $3.55 billion of revenue. The stock's current level sits well below its 52-week high of $247.49, but above the 200-day average of $183.37 is not far away.

DaVita Inc. company details

Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: NYSE
Price (as of August 31, 2026, 9:30 a.m. ET): $180.72 USD
Market cap: $11.53 billion
Sector / Industry: Health Care / Health Care Providers & Services
Index membership: S&P 500

Disclaimer...

en | US23918K1088 | DAVITA INC. | boerse | 70031880 | bgmi